Epidemic aluminum intoxication in hemodialysis patients traced to use of an aluminum pump. This study was designed to identify the source, risk factors, and clinical consequences of an outbreak of aluminum intoxication in hemodialysis patients using case-control and cohort studies, In
1991, a dialysis center in Pennsylvania [Dialysis Center A (DCA)]
identified a number of patients with elevated serum aluminum levels. All patients receiving dialysis at DCA during Januaiy 1, 1987 to March 26, 1992 were involved in the study. A case-patient was defined as any patient with a serum aluminum level 100 sgIliter after dialysis sessions at DCA. Fifty-nine case-patients were identified. Risk factors for elevated serum aluminum levels were receipt of bicarbonate-(rather than acetate-) based dialysate, higher number of sessions using bicarbonate dialysis, receipt of acid concentrate (used in bicarbonate dialysis) passed through one of two electric pumps, and a greater number of sessions using this concentrate. The electric pumps had an aluminum casing, casing cover, and impeller. Elevated levels of aluminum were found in acid concentrate after passing through a pump. Seizures and mental status changes requiring hospitalization were associated with aluminum exposure. We found that epidemic aluminum intoxication was caused by the use of an electric pump with aluminum housing to deliver acid concentrate used in bicarbonate dialysis. This outbreak demonstrates why it is essential to insure that all fluid pathways, storage tanks, central delivery systems, and pumps are compatible with low pH fluids before converting from acetate to bicarbonate dialysis.
Aluminum intoxication can cause dialysis encephalopathy, also called dialysis dementia [1] , a demineralizing osteodystrophy [2] , and anemia [3] . The two severe manifestations, dialysis encephalopathy and fracturing osteodystrophy, were reported as epidemic occurrences in hemodialysis centers worldwide from the late 1960's through the early 1980's [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . The source of these outbreaks was usually parenteral exposure to high concentrations of aluminum in water used in dialysate in areas where alum or aluminum sulfate was added as a flocculent to municipal water supplies. To address this problem, water treatment with reverse osmosis units or deionizers was shown to remove aluminum and other harmful chemicals [12, 13, 17, 18] , and the Association for the Advancement of Medical Instrumentation (AAMI) published standards for maximum aluminum levels in water used in dialysate Received for publication October 14, 1994 and in revised form February 1, 1995 Accepted for publication March 9, 1995 © 1995 by the International Society of Nephrology in 1981 [21] . Two other sources of epidemic aluminum intoxication in dialysis patients have been reported: a boiler aluminum anode that contaminated water used in dialysate [22] , and an aluminum-containing cartridge used in a sorbent regeneration system, which disintegrated and contaminated the dialysate [23] .
Currently, although aluminum intoxication in renal failure patients occurs sporadically due to oral aluminum-containing medications [24] [25] [26] [27] [28] , reports of the epidemic occurrence of aluminum intoxication in dialysis centers, with associated severe clinical manifestations, have virtually disappeared.
However, in 1991, a dialysis center in Pennsylvania [Dialysis Center A (DCA)], identified a number of patients with elevated serum aluminum levels. In 1988, structural renovations and the installation of electric pumps to deliver concentrates used in dialysate from the ground floor to the second floor had occurred. From 1988 through 1992, bicarbonate dialysis use had increased. When the initial investigation suggested contaminated dialysate, DCA discontinued use of the delivery system, and the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration were notified and assisted in the investigation.
Methods
Identification of patients with elevated serum aluminum levels To identify patients with elevated serum aluminum levels, we reviewed medical records of all DCA patients present during January 1, 1987 to March 26, 1992 (study period). Most patients had at least one, and commonly had quarterly, aluminum levels. Monthly aluminum testing was started in January 1992.
Case/noncase definitions Next, we defined a case-patient as any patient during the study period with a serum aluminum level 100 .rg/liter (normal 0 to 12) after 5 dialysis sessions at DCA. Aluminum levels measured after administration of deferoxamine, which can increase serum aluminum levels, were excluded. We defined a control or noncasepatient as any patient during the study period with a maximum serum aluminum level <100 pg/liter after 5 dialysis sessions at DCA.
Analysis of risk factors for elevated aluminum levels
Since the majority of case-patients had elevated aluminum levels after October 15, 1988 , the approximate date of installation March 26, 1992 . Sixty-four patients had a serum aluminum level 100 pg/liter during the study period; one patient with first aluminum level pg/liter before 1987 is not shown. In January 1992, a large number of patients with a serum aluminum level 100 gg/liter were identified due to a point prevalence survey. At A, two electric pumps were installed at DCA, approximately October 15, 1988 ; at B, acid concentrate was initiated through one pump, January 1, 1990; at C, acid concentrate was initiated through the second pump, February 1, 1992 ; at D, use of both pumps was discontinued, February 7, 1992. of the electric pumps, the epidemic period was defined as October 15, 1988 15, to February 7, 1992 . To determine risk factors for elevated aluminum levels during the epidemic period we randomly selected and compared 10 of the case-and 10 controlpatients. Because one of the identified risk factors was not present until after December 31, 1989, we next performed a cohort study of all DCA patients receiving dialysis during January 1, 1990 to February 7, 1992 , for a total of 102 (including 17 case-control study) patients. Twelve patients who did not have an aluminum level after January 1, 1990 and four who had a level but not after 5 dialysis sessions were excluded; most were only transiently dialyzed at DCA (<2 months). Risk factors evaluated included demographic factors, receipt of medications containing aluminum, and type of dialysate, dialyzer, and dialysis machine used. Dialysis sessions included were from the beginning of the period being evaluated (that is, October 15, 1988 for the case-control study or January 1, 1990 for the cohort study) until the date of the patient's subsequent maximum aluminum level, before deferoxamine.
Procedural investigation Laboratory investigation of environmental samples
Samples of acetate and bicarbonate dialysate, and acid, bicarbonate and acetate concentrate were collected for determination of aluminum levels. Aluminum assays were performed at Damon Clinical Laboratories, Inc. (Smyrna, GA, USA) or Serco Laboratories (St. Paul, MN, USA) using the atomic absorption method [29, 30] . One DCA electric pump was sent to CDC for examination and testing; acid concentrate was passed through the pump and tested for aluminum.
Laboratory investigation of autopsy specimens
Fresh autopsy specimens of brain from one patient suspected of having aluminum intoxication were sent to National Medical Services, Inc. (Willow Grove, PA, USA) for aluminum testing.
We reviewed the design and maintenance of DCA dialysate delivery and water treatment systems and water quality monitoring records. Patients with aluminum exposure were given deferoxamine stimulation tests and treated when appropriate with intravenous 0.5 to 1 g deferoxamine, usually administered weekly, until stimulated serum aluminum levels were similar to unstimulated levels. Patients present at DCA after February 7, 1992 were followed for one year.
Statistical methods
Data were entered into a microcomputer and analyzed using 
Results
During the study period, 64 patients had a serum aluminum level 100 jig/liter; many were identified in January 1992 due to testing of all patients (Fig. 1) . Thirteen of these had levels as high as 300 to 500 jig/liter; six had levels >500 jig/liter.
The proportion of patients with serum aluminum levels 100 jig/liter was higher during the period after the electric pumps were installed (October 15, 1988 to March 26, 1992) than before they were installed (January 1, 1987 to October 14, 1988); 60 of 133 (45%) versus 3 of 86 (3.5%), relative risk (RR) of 13, and P <0.0001 (analysis excludes one patient with a first serum aluminum level 100 jig/liter before the study period). Fifty-nine (92%) of the 64 patients with serum aluminum levels 100 jig/liter met the case definition.
Analysis of risk factors for elevated aluminum levels
Case-control study. Case-patients were significantly more likely than controls to have a higher number of dialysis sessions using bicarbonate dialysis (median 101 vs. 0, P = 0.01), higher number of sessions using acid concentrate (used in bicarbonate dialysis) passed through an electric pump (37.5 vs. 0, P = 0.02), or higher number of sessions using COBE Centrysystem 2 (COBE Laboratories, Inc., Lakewood, CO, USA) dialysis machines (12.5 vs. 0, P = 0.01).
Cohort study. Of 86 DCA patients included in the cohort study, 59 met the case definition. Risk factors were all those identified in the case-control study plus higher number of dialysis sessions, higher number of sessions using SPS45O (Baxter Healthcare Corporation, Largo, FL, USA) dialysis machines, receipt of predominantly bicarbonate dialysate, and receipt of acid concentrate passed through an electric pump (Table 1) . Age, gender, duration of dialysis at DCA, type of dialyzer, use of predominantly CUBE or SPS45O machines, or receipt of oral medications containing aluminum or citrate were not associated with becoming a case-patient. Receipt of acetate concentrate through an electric pump, higher number of sessions using acetate dialysate, and higher number of sessions using acetate concentrate through an electric pump were protective factors.
We controlled for the number of dialysis sessions by examining exposures only during the month before the maximum aluminum storage tank 1a storage tank 1, and after passing through the aluminum pump storage tank 1, and after passing through the aluminum pump storage tank 2b and after passing through the aluminum pump storage tank 1, and after passing through plastic pumpc storage tank 2, and after passing through plastic pump before entering machine before passing through When we stratified by receipt of acid concentrate through an electric pump, receipt of predominantly bicarbonate dialysis or use of predominantly COBE or SPS45O machines were not significant.
The maximum serum aluminum level (before deferoxamine) and number of dialysis sessions using acid concentrate through an electric pump were positively correlated (r 0.63).
Environmental and procedural investigation Before October 1988, acetate or acid concentrate was stored in 55 gallon drums and extracted using a hand pump. In October 1988, two 500-gallon storage tanks were introduced, which were located at ground level. Two electric pumps (Teel Industrial Series model 1P862, Dayton Electric Manufacturing Company, Chicago, IL, USA) were installed to pump fluid from the tanks to the second floor of DCA, via polyvinylchloride and vinyl pipes. From October 1988 through December 1989, both storage tanks contained acetate concentrate. In January 1990, because an increasing number of patients were being treated with bicarbonate dialysate, one tank was converted to acid concentrate for use with SPS45O dialysis machines. On February 1, 1992, the second tank was coaverted to acid concentrate, for use with COBE machines.
Laboratory investigation of autopsy specimens
Autopsy specimens of brain from one patient with encephalopathy had an elevated level of aluminum in the gray matter compared to that in the white matter; 8.2 and 2.0 pg/gm wet wt, respectively. This patient had 172 dialysis sessions of aluminum exposure and a maximum serum aluminum level of 642 jLg/liter.
Analysis of clinical characteristics of patients with aluminum exposure
Patients in the cohort study had 0 to 181 (median 50) dialysis sessions with aluminum exposure. Seventeen (20%) had hospitali.zations for mental status change or seizures. These patients had significantly more dialysis sessions with aluminum exposure than did patients without these problems (mental status change: median 92.5 vs. 40.5, P 0.0006; seizure: 109.5 vs. 45.5, P = 0.002).
Nine of the 17 patients had neurologic or systemic diseases unrelated to aluminum intoxication which could affect their mental status, such as cerebrovascular disease, pre-existing seizure disorder (previously controlled), amyloidosis, or pneumonia.
Characteristics of the eight patients without identifiable preexisting neurologic problems included seizures in 5 (63%), encephalopathy in 4 (50%), myoclonic jerks in 3 (38%), speech difficulty in 6 (75%), inappropriate behavior in 3 (38%), hallucinations in 2 (25%), dementia in 1 (13%), confusion in 7 (86%), disorientation in 6 (75%), and lethargy in 4 (65%). Clinical characteristics of the two groups did not differ significantly.
Fifteen (88%) of the 17 patients with hospitalizations for mental status change or seizures had onset before or within a few days after February 7, 1992 , when use of the aluminum pumps was xgIliter. This value is 8.1 to 840 times the maximum AAMI 870 recommended aluminum level in product water. When the DCA pump was set up at CDC, acid concentrate passed once through the pump, or left in the pump over a weekend and then flushed, had high levels of aluminum. The pH of selected acid concentrate samples was 2.6 and for acetate concentrate was 6.7. CDC CDC; single pass through aluminum pump CDC; after 3 days in aluminum pump discontinued. The other two patients had onset two months after this date. Bone fractures, or receipt of blood transfusions, erythropoietin or iron dextran injection were not associated with aluminum exposure.
Discussion
Epidemic aluminum intoxication occurred in DCA in association with the increased use of bicarbonate dialysis and the delivery of acid concentrate through an aluminum pump. Unlike previously reported epidemics, this outbreak occurred while an effective water treatment system was in place, and was due instead to a device used in the dialysate delivery system. The potential for similar epidemics may be increased because the percentage of U.S. dialysis centers using bicarbonate-based dialysate as their primary method of dialysis has increased from 22% in 1986 to 92% in 1991 [32] .
The two aluminum pumps installed at DCA in October 1988 were initially used to deliver acetate concentrate, which has a neutral pH. Subsequently, acid concentrate for 5P5450 machines was delivered through one aluminum pump during January 1990 to February 1992. Acid concentrate was used with the second aluminum pump only during a one week period in February 1992. Evidence implicating the aluminum pumps, and specifically the delivery of acid concentrate through one pump over a two year period includes the strong epidemiologic associations with receipt of acid concentrate through a pump, receipt of bicarbonate dialysate, higher number of sessions using 5P5450 machines, and the correlation between serum aluminum level and higher number of sessions with acid concentrate through a pump which suggests a dose-response. Laboratory results showing high levels of aluminum in acid concentrate which had passed through one pump and low levels in DCA samples taken after the pump was removed confirmed the aluminum-containing pump as the source of chemical contamination.
Factors contributing to the perpetuation of the outbreak over a two year period included case-patients being distributed among physician groups so individual physicians were not aware of the extent of the outbreak, variability in patients' serum aluminum levels causing confusion about their clinical significance, and receipt of oral aluminum phosphate binders by some patients who seemed therefore to have a plausible cause for their elevated serum aluminum level. Discontinuation of aluminum containing medications was often done concomitantly with a change in patients' dialysate to a low calcium bath. Aluminum levels improved, reinforcing the belief that discontinuation of these medications controlled the problem; however, in retrospect, the improvement was probably mainly due to the new bath which did not use acid concentrate through the aluminum pump.
Results of aluminum testing of autopsy specimens of brain tissue available from one patient were consistent with aluminum encephalopathy [33] [34] [35] [36] . Although similar data are not available for other patients, the epidemiologic association of seizures or mental status change with aluminum exposure supports our belief that the neurologic problems of a number of other patients were due to aluminum intoxication. In eight patients, these manifestations had no clear etiology and in retrospect may have been due to aluminum intoxication. Another nine patients had concomitant neurologic or systemic diseases that may have either solely accounted for their subsequent abnormalities or predisposed them to clinical manifestations of aluminum intoxication. Persons involved in the operation of dialysis centers should be aware of the potential for contamination of dialysate or water by aluminum or other chemicals. Flouride, chloramine, sulfate, nitrate, zinc, sodium azide, and copper can cause toxicity in dialysis patients, and many other chemicals pose a potential hazard [21, 29, [37] [38] [39] . Materials used in water treatment and dialysate delivery systems, including fluid pathways, storage tanks, central delivery systems, and pumps, should be compatible with all fluids in the system [21, 29, 37] . Modifications of the water treatment, dialysate delivery, or dialyzer reprocessing systems should only be made by personnel knowledgable about these systems and AAMI standards for water and dialysate used in hemodialysis. Based on this outbreak, the Food and Drug Administration sent a Safety Alert to U.S. dialysis centers recommending reassessment of the design of and components used in the water treatment, concentrate delivery transfer/storage, and dialysate delivery systems whenever changing or updating any component of an existing dialysis unit, and routine monitoring of serum aluminum levels in dialysis patients [40] .
